Pfizer (NYSE:PFE) Stock Price Down 1.3% – Here’s What Happened

Pfizer Inc. (NYSE:PFE)’s stock price fell 1.3% during trading on Friday. The stock traded as low as $29.81 and last traded at $30.0350. Approximately 29,374,521 shares traded hands during mid-day trading, a decline of 26% from the average session volume of 39,817,227 shares. The stock had previously closed at $30.42.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer signed a research collaboration and licensing agreement with Enodia Therapeutics focused on small-molecule Sec61 inhibitors. The deal gives Pfizer rights to discover, develop and potentially commercialize medicines from Enodia’s platform, adding potential value to Pfizer’s longer-term pipeline, although the programs remain early stage. Pfizer Signs New Drug Discovery Pact Focused on Sec61 Inhibitors
• Positive Sentiment: Pfizer completed a Phase 1 study for PF-07999415, providing an initial development milestone and additional information about the potential of its pipeline. However, the update does not yet establish efficacy or commercial prospects. Pfizer PF-07999415 Phase 1 Update
• Neutral Sentiment: New real-world data from Sweden’s Ibrance registry study could offer useful evidence about the drug’s performance in routine care. The report is potentially supportive for Pfizer’s oncology franchise, but the available information does not indicate a material change to near-term earnings. Pfizer Swedish Ibrance Study
• Neutral Sentiment: Pfizer’s roughly 5.7% dividend yield remains a major attraction for income investors and compares favorably with Merck’s. Analysts caution, however, that the high yield may reflect concerns about earnings and payout coverage rather than simply superior shareholder returns. Pfizer Dividend Yield Compared With Merck
• Negative Sentiment: Pfizer was swept into a selloff affecting Moderna and Merck after melanoma-vaccine results failed to meet the market’s very high expectations. Although Pfizer is not the primary company involved, the episode weakened sentiment across vaccine and biotechnology stocks. Melanoma Vaccine Selloff Spills Into Pfizer
• Negative Sentiment: Comparisons with Bristol Myers Squibb highlight Pfizer’s more uneven recent revenue performance, including year-over-year declines in several quarters. Higher interest rates may also reduce the appeal of high-yield stocks if safer fixed-income alternatives become more attractive. Bristol Myers Squibb Versus Pfizer Revenue Comparison

Analysts Set New Price Targets

A number of brokerages have issued reports on PFE. BMO Capital Markets decreased their price target on Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a report on Monday, July 13th. Weiss Ratings upgraded Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, August 31st. Bank of America cut their target price on Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Friday, July 10th. Scotiabank boosted their target price on Pfizer from $30.00 to $33.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 6th. Finally, Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Saturday, October 10th. Five investment analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $28.72.

Pfizer Stock Down 1.3%

The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96. The company has a market cap of $171.19 billion, a price-to-earnings ratio of 39.52, a P/E/G ratio of 2.03 and a beta of 0.32. The firm’s 50 day simple moving average is $28.26 and its 200-day simple moving average is $26.61.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%. The business had revenue of $15.03 billion for the quarter, compared to analysts’ expectations of $14.40 billion. During the same quarter in the previous year, the firm earned $0.78 earnings per share. The business’s revenue was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, December 7th. Shareholders of record on Friday, November 6th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 5.7%. The ex-dividend date is Friday, November 6th. Pfizer’s dividend payout ratio (DPR) is 226.32%.

Institutional Investors Weigh In On Pfizer

Several large investors have recently modified their holdings of the stock. Retirement Wealth Solutions LLC grew its position in Pfizer by 144.6% in the 3rd quarter. Retirement Wealth Solutions LLC now owns 861 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 509 shares during the last quarter. Evolution Wealth Management Inc. raised its position in Pfizer by 132.2% during the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 566 shares during the last quarter. Keb Asset Management LLC purchased a new position in Pfizer during the 2nd quarter worth $26,000. Field & Main Bank acquired a new stake in shares of Pfizer in the 2nd quarter worth $27,000. Finally, Global Trust Asset Management LLC lifted its stake in shares of Pfizer by 126.7% in the 1st quarter. Global Trust Asset Management LLC now owns 1,163 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 650 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.